Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Intervalo de año de publicación
1.
Neurología (Barc., Ed. impr.) ; 27(5): 301-310, jun. 2012. ilus, tab
Artículo en Español | IBECS | ID: ibc-102008

RESUMEN

Introducción: Realizar una revisión de la fisiología de las subunidades del receptor a glutamato tipo N-metil-D-aspartato (NMDA). Desarrollo: El acido glutámico (Glu) es el principal neurotransmisor excitador del sistema nervioso central la cual interactúa con dos tipos de receptores clasificados como: metabotrópicos y ionotrópicos. Los receptores ionotrópicos se dividen de acuerdo a la afinidad de sus agonistas específicos en: N-metil-D-aspartato (NMDA), ácido α-amino-3-hidroxi-5-metil-4-isoxazol (AMPA) y acido kaínico (KA). Los receptores NMDA son estructuras macromoleculares que se forman por combinaciones de diferentes subunidades: NMDAR1 (NR1), NMDAR2 (NR2) y (NR3). Conclusiones:El estudio de este receptor ha sido de gran interés por la función que desempeña en la plasticidad sináptica, pero sobre todo por la permeabilidad que tiene para el ion Ca++. En esta revisión se analiza la composición molecular del receptor NMDA, así como las distintas variantes de edición de la subunidad NR1 que en asociación con la subunidad NR2 forman el principal dímero de este receptor. La composición, estructura y funcionalidad y sus distintos patrones de expresión tanto temporal y espacial, ha permitido conocer la versatilidad y la diversidad funcional tanto de las diferentes isoformas de la subunidad NR1, así como las distintas propiedades farmacológicas de la subunidad NR2 (AU)


Introducion: To review the physiology of the glutamate receptor subunits such as N-methyl-D-aspartate (NMDA). Development:Glutamic acid (Glu) is the major excitatory neurotransmitter in the central nervous system which interacts with two types classified into two types: metabotropic and ionotropic. Ionotropic receptors are classified according to the affinity of their specific agonists: N-methyl-D-aspartate (NMDA), α-amino acid-3-hydroxy-5-methyl-4-isoxazole (AMPA) and kainic acid (KA). NMDA receptors are macromolecular structures that are formed by different combinations of subunits, NMDAR1 (NR1), NMDAR2 (NR2) and NMDAR3 (NR3). Conclusions: The study of this receptor has been of great interest due to its role in synaptic plasticity, but mainly due to the permeability it has to Ca++ ion. This review examines the molecular composition of NMDA receptor and the variants of NR1 subunit edition in association with NR2 subunit dimer, the main form of this receptor. The composition, structure and function and their distinct expression patterns in both time and space, has shown the versatility and diversity of functionally different isoforms of the NR1 subunit and various pharmacological properties of the NR2 subunit (AU)


Asunto(s)
Humanos , Receptores de Glutamato/fisiología , Receptores de N-Metil-D-Aspartato/fisiología , Plasticidad Neuronal/fisiología , Neurotoxinas/análisis , Ácido Glutámico/farmacocinética , Electrofisiología/métodos , Enfermedad de Alzheimer/fisiopatología , Enfermedad de Huntington/fisiopatología
2.
Neurologia ; 27(5): 301-10, 2012 Jun.
Artículo en Español | MEDLINE | ID: mdl-22217527

RESUMEN

INTRODUCTION: To review the physiology of the glutamate receptor subunits such as N-methyl-D-aspartate (NMDA). DEVELOPMENT: Glutamic acid (Glu) is the major excitatory neurotransmitter in the central nervous system which interacts with two types classified into two types: metabotropic and ionotropic. Ionotropic receptors are classified according to the affinity of their specific agonists: N-methyl-D-aspartate (NMDA), α-amino acid-3-hydroxy-5-methyl-4-isoxazole (AMPA) and kainic acid (KA). NMDA receptors are macromolecular structures that are formed by different combinations of subunits, NMDAR1 (NR1), NMDAR2 (NR2) and NMDAR3 (NR3) CONCLUSIONS: The study of this receptor has been of great interest due to its role in synaptic plasticity, but mainly due to the permeability it has to Ca(++) ion. This review examines the molecular composition of NMDA receptor and the variants of NR1 subunit edition in association with NR2 subunit dimer, the main form of this receptor. The composition, structure and function and their distinct expression patterns in both time and space, has shown the versatility and diversity of functionally different isoforms of the NR1 subunit and various pharmacological properties of the NR2 subunit.


Asunto(s)
Receptores de N-Metil-D-Aspartato/fisiología , Relación Estructura-Actividad
3.
HIV Med ; 6(6): 403-9, 2005 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-16268822

RESUMEN

OBJECTIVES: To describe the prevalence of baseline drug-resistance mutations, resistance to antiretroviral drugs, and the subsequent virological response to therapy in treatment-naïve patients from Mexico with established HIV-1 infection. METHODS: Resistance testing was performed on plasma samples from antiretroviral-naïve patients. Data on mutations associated with antiretroviral drug resistance were obtained using Stanford software (http://hivdb.stanford.edu). RESULTS: Ninety-six treatment-naïve individuals were enrolled in the study during 2002-2003. Of these, 83 patients (86%) had at least one resistance mutation and 15 (16%) had drug resistance. At baseline, the mean plasma viral load was 299 834 HIV-1 RNA copies/mL, and at follow-up it was 37 620 copies/mL (P<0.0001). Primary mutations in the reverse transcriptase region were observed in 15% of patients. For nucleoside inhibitors, mutations T215Y/C and F77L (3%) and D67N/S, T69N and M184V (2%), were detected. For nonnucleoside inhibitors, mutations K103N/R (6%), Y181C (3%) and G190A (2%) were detected. Overall, 6% of patients showed resistance to delavirdine and nevirapine, 4% to efavirenz, and 2% to lamivudine and nelfinavir. Twelve patients showed no response to treatment and three of these patients had antiretroviral drug resistance. CONCLUSIONS: The prevalence of baseline drug-resistance mutations found in this study was similar to that found in previous reports for newly HIV-infected individuals, although access to and management of antiretrovirals in Mexico are different.


Asunto(s)
Farmacorresistencia Viral/genética , Infecciones por VIH/virología , VIH-1/genética , Mutación , Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa , Femenino , Estudios de Seguimiento , Infecciones por VIH/tratamiento farmacológico , Proteasa del VIH/genética , Transcriptasa Inversa del VIH/antagonistas & inhibidores , Transcriptasa Inversa del VIH/genética , VIH-1/efectos de los fármacos , VIH-1/aislamiento & purificación , Humanos , Masculino , Estudios Prospectivos , ARN Viral/sangre , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Resultado del Tratamiento , Carga Viral
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA